Fri, Apr 18, 2014, 10:59 PM EDT - U.S. Markets closed for Good Friday


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

medtrust2 46 posts  |  Last Activity: Apr 11, 2014 9:36 AM Member since: Mar 13, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Never was, this evening confirmed it. Psoriasis was just a quick way of ensuring safety of IMO-8400. The real prize is coming. Smart guys. Nothing ever changed. We'll be trading above $6 in a week.

  • They are narrowly targeting very specific genetic mutations in orphan indications for which they are certain about achieving maximum efficacy with their TLR Antagonist platform. This strategy maximizes successful trial results and shortens time to market. It's seems to be a very deliberate strategy, and one that apparently Baker Bros likes.

    I'd also bet they will partner IMO-8400 for the Psoriasis indication shortly after the Phase 2 results are announced. That's another quick way to bring in lots of cash to further implement their long term strategy.

    Smart management.

  • The same people that will be issuing the upgrades tomorrow and Wednesday. It's all a big game.

  • What a great weekend it's gonna be!

  • That's confidence. Most companies would be in a panic if their stock dropped 21% in a day. These guys know the results, and don't appear concerned. I like that!

  • In case you forgot the effectiveness of Idera's Toll Antagonist. IMO-8400 should be even better. Consider today's manipulation by SS a gift:

    The clinical-stage biotechnology company Idera Pharmaceuticals has announced the results of a Phase IIa trial that demonstrate positive results for IMO-3100, a drug in development for moderate-to-severe plaque psoriasis.

    Nearly half (48%) of the 25 psoriasis patients treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90%. The randomized, double blind, placebo-controlled trial utilized two dose levels of IMO-3100 administered for 4 weeks, with a 4-week follow-up period. Among evaluable patients, the median PASI scores at treatment initiation were 14.9, 16.1 and 12.5 in the 0.16 mg/kg, 0.32 mg/kg and placebo cohorts, respectively.

    Change in epidermal thickness was the primary endpoint for this trial, according to news reports. Skin biopsies were collected at baseline and after completion of treatment to investigate changes in epidermal thickness and immune cell infiltrates. Patients receiving IMO-3100 had a median change in epidermal thickness of -6.4%, compared to a median change of +7.7% for placebo-treated patients.

  • Consolidation today, shares get loaded ahead of tomorrow's presentation. Upgrade as soon as Wednesday. Friday we close at a new 52 week high. It's the way the game is played.

  • Where's Orbimed, Baker Bros, FMR, etc? Did they actually miss this Biotech, or do they know something all the retail investors don't? Something isn't right here. Think about it.

  • Regular occurrence here with IDRA, and then it closes green. Got my order in at $6.01. Hopefully it fills.

  • medtrust2 by medtrust2 Feb 12, 2014 10:30 AM Flag

    Why is this dropping?

  • 9 Person company, with no products on the market, or revenue, located somewhere in Australia. 2 Trials running with less than 170 patients, and no major institutional ownership to speak of. And it has a market cap over 500 Million? Seriously? Tell me why I should by it at these levels?

  • medtrust2 medtrust2 Mar 25, 2014 9:52 AM Flag

    How is that? I'm still holding my shares. And if you continue to hold through the 31st, you won't loose a penny either. Probably will even make more as this takes off past $7.

  • Oh, and there are two Form 4 filings last Wednesday with buys at $6.06. Thanks for the cheap shares.

  • Reply to

    Baker Brothers added

    by j.brantz2 Mar 19, 2014 12:24 AM
    medtrust2 medtrust2 Mar 19, 2014 7:51 AM Flag

    I know there overweight IDRA, glad to see their onboard with DSCO too! They must like Aerosurf. Great stuff.

  • After today those options (converted just last Wednesday) aren't worth anything. You think Baker Bros and Goldberg would have converted options and acquired shares if they thought bad news was coming?

  • Reply to

    Is this Prana's corporate office?

    by medtrust2 Jan 30, 2014 10:17 PM
    medtrust2 medtrust2 Jan 30, 2014 10:56 PM Flag

    When you purchase shares of a company, it's assets are part of it. Also good DD always includes checking out the entire story. Based on the G street view, they either operate out of an Arcade or the clothing store across the street. Your comfortable investing your money in that?

  • Take a look at the street view on goog maps:

    Suite 2, 1233 High Street, ARMADALE, VIC, AUSTRALIA, 3143

    This is a 500+ million dollar company?

  • medtrust2 medtrust2 Jan 22, 2014 9:42 AM Flag

    Can't argue with my point though. No serious institutions are touching Prana. Makes you wonder why....

  • This was announced by Critical Diagnostics in February 2014 by a study conducted at Mass General. It would seem to suggest that for patients with chronic heart failure due to left ventricular systolic dysfunction, SST2 is a far better predictor than Galectin-3. One of the conclusions of the study was "Evaluating Galectin-3 by BG Medicine in the same study cohort once again showed ST2’s superiority over Galectin-3." Additional detail:

    The investigators in the Massachusetts General Hospital study, using the same cohort of patients, recently examined another biomarker, galectin-3 by BG Medicine. Those results were published earlier last year [“Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study,” in the European Journal of Heart Failure, May 10, 2013].

    While a September 23, 2013 press release from BG Medicine about this paper stated, “elevated levels of galectin-3 are predictive of adverse outcomes in chronic heart failure patients and suggest that the prognostic value of this non-invasive biomarker may be enhanced when serial measurements are made over time,” the study’s authors note in their paper, “In fully adjusted multivariate Cox proportional hazard models, however, neither baseline nor subsequent galectin-3 levels had a significant effect on the prediction of time to first CV [cardiovascular] event.”

  • Reply to


    by isochroma2 Mar 24, 2014 9:13 PM
    medtrust2 medtrust2 Mar 24, 2014 9:59 PM Flag

    You're not a very good liar are you? When I click on Clinical Trials you get (noticed which one is listed first).

    "The Company has two ongoing clinical programs:

    Autoimmune Diseases

    Idera has completed a clinical proof-of-concept study in patients with moderate-to-severe plaque psoriasis with a treatment duration of 4 weeks. Based on the results of this trial, Idera is evaluating its lead compound, IMO-8400, in a randomized, double-blind, placebo-controlled Phase 2 trial in moderate-to-severe plaque psoriasis with a treatment duration of up to 12 weeks. In September 2013 Idera completed enrollment of the 32 patients initially planned in this trial. While the dosing in the trial is ongoing and the data remain blinded, all treatments have been well-tolerated to date. Based on this positive safety profile, the Company has expanded the trial to include a higher dose cohort of 0.6 mg/kg and placebo in up to 12 patients. The Company plans to consider further dose escalation based on the safety and tolerability observed in the expansion cohort. Idera expects top-line data from the first three dosing groups to be available by the end of the first quarter of 2014 and top-line data from the expansion cohort to be available by the end of the second quarter of 2014. Additional details on the trial are available on

    Idera has begun a strategic review of orphan autoimmune indications suited to TLR antagonist therapy, and expects to identify priority indications in early 2014.

    Idera has selected IMO-9200, its second novel antagonist of TLR 7, 8, and 9 for development in select autoimmune disease indications. The Company has initiated IND-enabling studies for IMO-9200 and expects this compound to be available for clinical development in the second half of 2014.

    Genetically Defined Forms of B-cell Lymphoma

    Idera has opened enrollment in a Phase 1/2 trial of IMO-8400 in patients with Waldenström’s...

3.97-0.07(-1.73%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
SandRidge Energy, Inc.
NYSEThu, Apr 17, 2014 4:01 PM EDT